Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures V. L.P. 5Am sold 20,065 shares of Entrada Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $150,487.50. Following the completion of the sale, the insider directly owned 3,163,066 shares in the company, valued at approximately $23,722,995. This represents a 0.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Entrada Therapeutics Price Performance
Shares of TRDA traded up $0.25 during trading hours on Monday, hitting $6.80. The company's stock had a trading volume of 94,423 shares, compared to its average volume of 134,703. The business has a 50 day simple moving average of $7.68 and a two-hundred day simple moving average of $10.21. Entrada Therapeutics, Inc. has a 52-week low of $6.48 and a 52-week high of $21.79. The company has a market cap of $258.08 million, a price-to-earnings ratio of 8.40 and a beta of -0.11.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 14.39% and a return on equity of 5.84%. The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. Research analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
TRDA has been the topic of several research analyst reports. Wall Street Zen upgraded Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $25.67.
Check Out Our Latest Analysis on TRDA
Institutional Investors Weigh In On Entrada Therapeutics
Several institutional investors have recently made changes to their positions in TRDA. Harbor Capital Advisors Inc. raised its stake in shares of Entrada Therapeutics by 14.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 15,277 shares of the company's stock valued at $103,000 after purchasing an additional 1,874 shares during the period. Strs Ohio bought a new stake in shares of Entrada Therapeutics during the first quarter valued at about $378,000. Trexquant Investment LP purchased a new stake in shares of Entrada Therapeutics in the first quarter worth about $101,000. WCG Wealth Advisors LLC boosted its position in shares of Entrada Therapeutics by 20.0% in the first quarter. WCG Wealth Advisors LLC now owns 28,830 shares of the company's stock valued at $261,000 after acquiring an additional 4,800 shares during the period. Finally, Merck & Co. Inc. purchased a new position in Entrada Therapeutics during the first quarter valued at approximately $15,728,000. Hedge funds and other institutional investors own 86.39% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
